CIDP and length-dependent peripheral neuropathy differ in mechanism, distribution and timeline. CIDP — chronic inflammatory demyelinating polyradiculoneuropathy — is immune-mediated inflammation of the nerve roots and peripheral nerve, and its symptoms must persist for at least 8 weeks to establish the diagnosis [1]. Length-dependent neuropathy instead follows the length of the nerve fiber, so assessment starts distally at the dorsal aspect of the great toe on both sides and moves upward [3].
That difference is not academic. It changes which pattern your clinician is looking for, which tests are worth running, and in what order.
What CIDP is
CIDP is immune-mediated, involving inflammation of both nerve roots and peripheral nerve [1]. Its pathology is segmental demyelination and remyelination, and repeated cycles of that process produce the concentrically arranged Schwann cells known as onion bulbs [1].
Because nerve roots are involved, the weakness does not stay in the feet. The typical presentation is symmetric progressive proximal and distal muscle weakness with distal numbness evolving over at least eight weeks [2].
Course
CIDP can be monophasic, relapsing or progressive, with roughly one-third of patients experiencing a relapsing-remitting pattern and others showing steady progression [1]. A course that flares and settles is one of the features that raises the question.
Which sensations are affected
CIDP particularly affects position and vibration sense more than pain and temperature, which reflects predominant large-fiber involvement [1]. Patients often describe unsteadiness and a sense that they cannot tell where their feet are, rather than burning.
What length-dependent neuropathy is
Length-dependent neuropathy is the pattern in which the longest nerve fibers are affected first, so symptoms begin in the toes and progress upward. In diabetes, the American Diabetes Association describes assessment as following the typical distal symmetric polyneuropathy pattern, starting distally at the dorsal aspect of the great toe on both sides and moving proximally [3].
Which sensations are affected
The most common early symptoms come from small-fiber involvement and include pain and dysesthesias — unpleasant burning sensations — described as burning, lancinating, tingling or shooting [3]. Large-fiber involvement causes numbness, tingling without pain, and loss of protective sensation, which marks more advanced neuropathy and raises the risk of foot ulceration [3].
What that pattern means in practice, and how it is examined, is covered in peripheral neuropathy of the feet, symptoms and patterns.
The comparison, side by side
This is a guide to what to ask and what to test, not a self-diagnosis tool. Your clinician makes the diagnosis.
Distribution
Length-dependent neuropathy begins distally and climbs [3]. CIDP involves nerve roots as well as peripheral nerve, and presents with proximal as well as distal weakness [1][2].
Sensory profile
CIDP emphasizes position and vibration sense over pain and temperature [1]. Length-dependent disease more often opens with small-fiber symptoms, meaning burning and other painful dysesthesias [3].
Timeline
CIDP requires persistence of at least eight weeks [1][2]. Length-dependent neuropathy accumulates more gradually and tracks the driver behind it — metabolic, nutritional, toxic, autoimmune or structural.
How common each is
CIDP incidence is estimated at 0.15 to 1.6 cases per 100,000 person-years and prevalence at 0.67 to 10.3 per 100,000, with onset typically between 40 and 60 years and a male-to-female ratio of about 2:1 [2]. Distal symmetric polyneuropathy in diabetes is far more common: it affects at least 20% of people with type 1 diabetes after 20 years, and ranges from 10% to 15% of newly diagnosed patients with type 2 diabetes to 50% after 10 years [3].
When to raise the CIDP question
Certain features should prompt the question rather than settle it.
- Weakness that is not confined to the feet, including proximal weakness [1][2]
- Symptoms that have persisted and evolved beyond eight weeks [1]
- Sensory loss that emphasizes vibration and position sense over pain and temperature [1]
- A course that includes relapses rather than steady distal progression [1]
If your symptoms are changing rapidly, if weakness is severe, or if breathing is affected, that is an emergency evaluation, not a scheduled one.
How the evaluation is sequenced here
We perform electrodiagnostic testing (EMG and nerve conduction studies) on site and read it alongside your symptom distribution, examination findings and likely drivers. Because CIDP is uncommon and length-dependent causes are not, the order of the workup follows your pattern and timeline rather than a fixed checklist.
Where the pattern points to a metabolic, nutritional, toxic or structural driver, testing and diagnosis drive the plan rather than the reverse. That sequence is set out in the Regenerve Protocol for peripheral neuropathy.
What we do not do
We do not treat labels, and we do not promise nerve regeneration or reversal of established nerve damage. If the pattern suggests an immune-mediated process such as CIDP, that belongs with the clinicians who manage immune therapy, and our role is to help get the question asked.
Frequently asked questions
How long do symptoms have to last before CIDP is considered?
At least eight weeks. CIDP symptoms must persist for at least 8 weeks to establish the diagnosis [1], and the typical presentation is symmetric progressive proximal and distal muscle weakness with distal numbness evolving over that period [2]. Burning that comes and goes over days is a different question — see small fiber neuropathy symptoms and testing.
Does burning in my feet point toward CIDP?
Usually the opposite. CIDP particularly affects position and vibration sense more than pain and temperature [1], while burning and other unpleasant burning sensations are the early small-fiber symptoms of distal symmetric polyneuropathy [3]. What follows from that distinction is covered in peripheral neuropathy treatments for the feet.
Is CIDP common?
No. Incidence is estimated at 0.15 to 1.6 cases per 100,000 person-years and prevalence at 0.67 to 10.3 per 100,000 people, with onset typically between ages 40 and 60 and males affected about twice as often as females [2]. That rarity is why the more common drivers are usually worked through first — our sequence is described in our neuropathy services.
Should I bring my medication list to the evaluation?
Yes, and the full list including anything started or stopped in the last few years. Medication history is one of the categories we review alongside metabolic, nutritional, toxic and autoimmune drivers. Our discussion of the medications patients ask about most is at statins, metformin and nerve health.
Start with the Nerve Damage Score
The Nerve Damage Score is a free five-question assessment that helps identify which driver is most likely behind your symptoms, so your evaluation starts with a direction instead of a guess.
Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Serving the St. Louis region, Missouri and Illinois, minutes from St. Louis Lambert International Airport.
Sources
- Gogia B, Rocha Cabrero F, Khan Suheb MZ, Lui F, Rai PK. “Chronic Inflammatory Demyelinating Polyradiculoneuropathy.” In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Last updated 4 March 2024. https://www.ncbi.nlm.nih.gov/books/NBK563249/ — cited for the requirement that symptoms persist at least 8 weeks to establish the diagnosis; inflammation of nerve roots and peripheral nerve; segmental demyelination and remyelination producing onion bulbs; the monophasic, relapsing and progressive courses with about one-third relapsing-remitting; and involvement of position and vibration sense more than pain and temperature.
- “Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy.” Practical Neurology, April 2024 issue. https://practicalneurology.com/diseases-diagnoses/neuromuscular/diagnosis-of-chronic-inflammatory-demyelinating-polyneuropathy/32112/ — cited for the typical presentation of symmetric progressive proximal and distal muscle weakness with distal numbness evolving over at least 8 weeks; the progressive, monophasic and relapsing-remitting courses; incidence of 0.15 to 1.6 cases per 100,000 person-years; prevalence of 0.67 to 10.3 per 100,000; onset around 40 to 60 years; and the approximately 2:1 male-to-female ratio.
- Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. “Diabetic Neuropathy: A Position Statement by the American Diabetes Association.” Diabetes Care, 2017;40(1):136–154. DOI: 10.2337/dc16-2042. https://pmc.ncbi.nlm.nih.gov/articles/PMC6977405/ — cited for assessment following the typical distal symmetric polyneuropathy pattern starting distally at the dorsal aspect of the great toe on both sides and moving proximally; small-fiber symptoms of pain and burning dysesthesias described as burning, lancinating, tingling or shooting; large-fiber symptoms of numbness, tingling without pain and loss of protective sensation; and prevalence of at least 20% in people with type 1 diabetes after 20 years and 10–15% of newly diagnosed type 2 patients rising to 50% after 10 years.